Cowen & Co. Thinks Five Prime Therapeutics’ Stock is Going to Recover
Cowen & Co. analyst Chris Shibutani maintained a Buy rating on Five Prime Therapeutics (FPRX) today. The company’s shares closed yesterday at $5.25, close to its 52-week low of $4.89.
According to TipRanks.com, Shibutani is a 4-star analyst with an average return of 4.2% and a 40.0% success rate. Shibutani covers the Healthcare sector, focusing on stocks such as Pieris Pharmaceuticals, Evelo Biosciences Inc, and Nektar Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Five Prime Therapeutics with a $10 average price target.
See today’s analyst top recommended stocks >>
Based on Five Prime Therapeutics’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $35.39 million. In comparison, last year the company had a GAAP net loss of $34.06 million.
Based on the recent corporate insider activity of 43 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of FPRX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on discovering and developing novel protein therapeutics. product candidates includes, Cabiralizumab(FPA008), Bemarituzumab(FPA144), and FPA150.